The pharmaceutical sector is dealing with numerous regional and international

developments. Nonetheless, a few significant trends—including the development of digital

and analytics tools—indicate a sector tailwind.
The world of products is likewise evolving quickly. The drug research pipeline now includes
new modalities at a rate of 21 percent, the most significant rate of growth ever recorded in
the industry. Examples include cell and gene therapy and mRNA vaccination technology.
More technological fragmentation, novel supply chains, and distinctive product life cycles
are anticipated to result from this transition.
Industry-specific changes and general global trends, like supply chain concerns, have
impacted pharma. Even though the pharmaceutical business has significant inventory levels
and long-standing dual sourcing, the likelihood of supply chain interruptions still carries a
potential loss of 25% of EBITA over a ten-year timeframe. Recent months have seen
unprecedented levels of inflation, which has increased the price of labor, raw commodities,
and transportation. This is in addition to the ongoing price pressures that pharma already
faces, especially concerning generics. Profit margins are under strain because pharma clients
will likely only partially absorb these cost hikes.
Due to broader labor market trends, such as the 20% rise in demand for STEM-related
positions across the US life sciences sector, the pharmaceutical business is also experiencing
a talent shortage. The need for digital pharma skills is currently at least 14% higher than the
supply, and many companies need help finding technical talent. The rise of remote work,
which has raised employee expectations for flexibility, exacerbates this problem. , almost all
pharmaceuticals are testing with hybrid working models.